Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solasia Pharma, a developer of Western oncology pharmaceuticals in-licensed for commercialisation in Asian markets, has entered into a license and supply agreement with Kyowa Hakko Kirin.
Subscribe to our email newsletter
The agreement provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (extended release transdermal granisetron patch; brand name: Sancuso) in Taiwan, Hong Kong, Singapore and Malaysia.
Earlier, in May 2008, Solasia had acquired the exclusive right to Sancuso from ProStrakan Group for Japan, China and other territories in Asia.
Reportedly, Solasia retains full rights in Japan and China where it is currently conducting Sancuso clinical development activities. Sancuso was approved in the US in September 2008 for the prevention of chemotherapy-induced nausea and vomiting.
As per the terms of the agreement, Solasia is expected to receive upfront, regulatory and sales milestones. Kyowa Hakko Kirin will be responsible for all commercialisation activities in Taiwan, Hong Kong, Singapore and Malaysia. Solasia will supply product to Kyowa Hakko Kirin in these territories.
Steve Engen, president of Solasia, said: “We are very excited to build upon our strong relationship with Kyowa Hakko Kirin, and look forward to seeing Sancuso launched in these Asian territories in the near future.”